Skip to main content
. 2026 Apr 16;11(7):106545. doi: 10.1016/j.ekir.2026.106545

Figure 2.

Figure 2

Proportion of participants with a UACR reduction of ≥ 30% from baseline to end of treatment at week 14. EMPA, empagliflozin; KDIGO, Kidney Disease: Improving Global Outcomes; KFRE, kidney failure risk equation; PBO, placebo; UACR, urine albumin-to-creatinine ratio; VICA, vicadrostat.